Verona Pharma plc (VRNA)
Automate Your Wheel Strategy on VRNA
With Tiblio's Option Bot, you can configure your own wheel strategy including VRNA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol VRNA
- Rev/Share 0.1745
- Book/Share 0.3335
- PB 35.3502
- Debt/Equity 0.0094
- CurrentRatio 8.8608
- ROIC -0.3089
- MktCap 8015209471.0
- FreeCF/Share -0.1772
- PFCF -66.5872
- PE -48.8359
- Debt/Assets 0.0041
- DivYield 0
- ROE -0.8989
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | VRNA | TD Cowen | -- | Buy | -- | $100 | April 28, 2025 |
| Initiation | VRNA | Cantor Fitzgerald | -- | Overweight | -- | $80 | April 21, 2025 |
| Initiation | VRNA | ROTH MKM | -- | Buy | -- | $68 | Jan. 10, 2025 |
| Initiation | VRNA | Wells Fargo | -- | Overweight | -- | $50 | Oct. 3, 2024 |
News
Verona Pharma Announces June 2025 Investor Conference Participation
Published: May 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
LONDON and RALEIGH, N.C., May 21, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will participate in fireside chats at the following conferences in June 2025:
Read More
Verona Pharma to Present Seven Analyses of the Phase 3 ENHANCE Studies in COPD at ATS 2025
Published: May 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
Analyses support Ohtuvayre® (ensifentrine) as a first-in-class selective dualinhibitor of PDE3 and PDE4 for a broad COPD population
Read More
Silencing The Doubters: Verona Pharma Could Be Sitting On A Blockbuster
Published: May 01, 2025 by: Seeking Alpha
Sentiment: Positive
VRNA's COPD drug Ohtuvayre shows impressive Q1'25 net sales of $71.3M in just its third quarter of sales, all but confirming the blockbuster future of the drug. Ongoing R&D and trials, including a phase 3 trial in China that should readout in Q2'25, represent future clinical catalysts. A partnership in the UK or Europe is another potential near-term catalyst, although if the terms are not favorable, that could impact the performance of the stock.
Read More
Verona Pharma plc (VRNA) Q1 2025 Earnings Call Transcript
Published: April 29, 2025 by: Seeking Alpha
Sentiment: Neutral
Verona Pharma plc (NASDAQ:VRNA ) Q1 2025 Earnings Conference Call April 29, 2025 9:00 AM ET Company Participants Victoria Stewart - Senior Director, Investor Relations and Communications David Zaccardelli - President and CEO Mark Hahn - CFO Christopher Martin - CCO Tara Rheault - Chief Development Officer Kathleen Rickard - Chief Medical Officer Conference Call Participants Andrew Tsai - Jefferies Yasmeen Rahimi - Piper Sandler Olivia Brayer - Cantor Fitzgerald Tara Bancroft - TD Cowen Tiago Fauth - Wells Fargo Thomas Shrader - BTIG Ram Selvaraju - HCW Sushila Hernandez - Van Lanschot Kempen Boobalan Pachaiyappan - ROTH Operator Welcome …
Read More
Verona Pharma Reports First Quarter 2025 Financial Results and Provides Corporate Update
Published: April 29, 2025 by: GlobeNewsWire
Sentiment: Neutral
Total net revenue of $76.3 million from Q1 2025 driven by Ohtuvayre ® net sales of $71.3 million (+95% vs Q4 2024)
Read More
Verona Pharma's Bull Case Holds, But Lifecycle Extension Is Critical
Published: April 07, 2025 by: Seeking Alpha
Sentiment: Positive
Ohtuvayre's robust launch for COPD treatment exceeded expectations, with Q4 revenue of $36.6 million and FY24 revenue of $42.3 million, indicating strong market demand. Verona's financial health is solid with $399.757 million in cash, providing a cash runway into 2028, despite a net loss of $33.8 million in Q4. Verona is extending Ohtuvayre's life cycle through new formulations and fixed-dose combinations, aiming for cash flow break-even with a quarterly run rate near $300 million.
Read More
Verona Pharma plc (VRNA) Q4 2024 Earnings Call Transcript
Published: February 27, 2025 by: Seeking Alpha
Sentiment: Neutral
Verona Pharma plc (NASDAQ:VRNA ) Q4 2024 Earnings Conference Call February 27, 2024 9:00 AM ET Company Participants David Zaccardelli - President and CEO Mark Hahn - CFO Christopher Martin - CCO Conference Call Participants Andrew Tsai - Jefferies Yasmeen Rahimi - Piper Sandler Tiago Fauth - Wells Fargo Tom Shrader - BTIG Ram Selvaraju - HCW Joon Lee - Truist Boobalan Pachaiyappan - ROTH Operator Good morning ladies and gentlemen. Welcome to the Verona Pharma Fourth Quarter and Full Year 2024 Financial Results and Conference Call.
Read More
Verona Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Published: February 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
Ohtuvayre TM (ensifentrine) recorded net product sales of $36.6 million in Q4 and $42.3 million in 2024
Read More
Verona Pharma Announces March 2025 Investor Conference Participation
Published: February 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
LONDON and RALEIGH, N.C., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at the following conferences in March 2025:
Read More
Verona Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update
Published: February 13, 2025 by: GlobeNewsWire
Sentiment: Neutral
LONDON and RALEIGH, N.C., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the fourth quarter and full year ended December 31, 2024 on Thursday, February 27, 2025 and host an investment community conference call at 9:00 a.m. EST / 2:00 p.m. GMT to discuss these financial results and provide a corporate update.
Read More
What Makes Verona Pharma (VRNA) a Good Fit for 'Trend Investing'
Published: February 12, 2025 by: Zacks Investment Research
Sentiment: Positive
If you are looking for stocks that are well positioned to maintain their recent uptrend, Verona Pharma (VRNA) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Read More
About Verona Pharma plc (VRNA)
- IPO Date 2017-04-28
- Website https://www.veronapharma.com
- Industry Biotechnology
- CEO Dr. David S. Zaccardelli Pharm.D.
- Employees 209